Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEnliven Therapeutics Inc.

Enliven Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
50.9 USD 1.47 ( 2.97%)
Last update at 2026-11-09T17:47:00Z
VOLUME
195357
Market Cap
3909.73M

Momentum Score

…

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
48.77
Low
51.58
High
52 Week Price Range
14.79
Low
62.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ (ELVN) that develops oncology therapeutics, based on its public filings and company disclosures. Its long-term growth drivers may include progression of clinical programs, regulatory milestones and strategic partnerships that could support pipeline advancement, and investors may find exposure to clinical-stage drug development attractive for potential upside tied to trial readouts.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
49.43
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-15.31%
Net Debt
-98.50M
ROCE
-26.04%
Diluted EPS TTM
-1.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -103.69M -88.79M -71.58M -37.66M -24.74M
Net income -103.69M -89.02M -71.58M -37.75M -24.72M
Selling general administrative 33.80M 23.78M 18.95M 7.77M 4.29M
Selling and marketing expenses - - 18.94M - -
Gross profit -0.26M -0.32M -0.30M - -
Reconciled depreciation 0.26M 0.32M 0.30M 0.21M 0.12M
Ebit -119.66M -104.55M -83.53M -38.79M -24.76M
Ebitda -119.39M -104.24M -83.23M -38.58M -24.65M
Depreciation and amortization 0.26M 0.32M 0.30M 0.21M 0.12M
Operating income -119.66M -104.55M -83.53M -38.79M -24.76M
Other operating expenses 119.66M 104.55M 83.53M 38.79M 24.76M
Interest expense - - - -1.22M 0.09M
Tax provision 0.00M 0.23M 0.00M - -
Interest income 16.01M 14.89M 11.97M 1.13M 0.02M
Net interest income 16.01M 14.89M 11.97M 1.13M 0.02M
Income tax expense - 0.23M 1.30M 0.09M -0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 119.39M 104.55M 83.53M 38.79M 24.76M
Cost of revenue 0.26M 0.32M 0.30M - -
Total other income expense net 15.96M 15.76M 11.95M 1.13M 0.02M
Net income from continuing ops -103.69M -89.02M -71.58M -37.66M -24.74M
Net income applicable to common shares - - - - -24.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 476.17M 325.76M 271.87M 83.30M 113.33M
Other current assets 12.26M 4.69M 12.95M 2.22M 0.65M
Total liab 16.68M 15.91M 25.96M 160.12M 156.22M
Total stockholder equity 459.60M 309.85M 245.91M -76.83M -42.89M
Deferred long term liab - - - - 1.65M
Other current liab 14.01M 14.57M 25.03M 0.45M 0.37M
Common stock 0.06M 0.05M 0.04M 0.00M 0.00M
Capital stock 0.06M 0.05M 0.04M 0.00M 0.00M
Retained earnings -347.17M -243.47M -154.45M -82.86M -45.20M
Other assets - - - - 1.71M
Cash 98.90M 124.12M 100.19M 75.54M 110.02M
Total current liabilities 16.57M 15.91M 25.89M 9.71M 5.75M
Current deferred revenue - - - 5.51M 2.70M
Net debt -98.50M -124.12M -99.86M -75.21M -109.86M
Short term debt 0.40M - 0.34M 0.32M 0.16M
Short long term debt total 0.40M - 0.34M 0.32M 0.16M
Other stockholder equity 806.37M 553.21M 128.31M 6.04M 2.31M
Property plant equipment - - - - 0.95M
Total current assets 474.88M 318.13M 266.15M 77.75M 110.67M
Net tangible assets - - - - -42.89M
Short term investments 363.73M 189.32M 153.01M - -
Accounts payable 2.16M 1.34M 0.53M 3.44M 2.52M
Accumulated other comprehensive income 0.33M 0.06M 0.14M - -0.02M
Non currrent assets other 0.87M 7.17M 4.65M 4.03M 1.71M
Non current assets total 1.29M 7.63M 5.72M 5.54M 2.66M
Capital lease obligations 0.40M 0.00M 0.34M 0.32M 0.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -173.90M -36.00M -148.41M -0.61M -0.19M
Change to liabilities - - - - 1.73M
Total cashflows from investing activities -173.84M -36.00M -148.41M - -0.19M
Total cash from financing activities 218.87M 133.16M 234.29M -1.80M -1.02M
Change to operating activities - - - - 1.83M
Net income -103.69M -89.02M -71.58M -37.66M -24.74M
Change in cash -25.27M 23.98M 24.61M -34.49M -20.34M
Begin period cash flow 124.17M 100.19M 75.59M 110.08M 130.42M
End period cash flow 98.90M 124.17M 100.19M 75.59M 110.08M
Total cash from operating activities -70.30M -73.19M -61.27M -32.08M -19.13M
Issuance of capital stock 216.17M 39.19M 0.00M 0.59M 0.69M
Depreciation 0.26M 0.32M 0.30M 0.21M 0.12M
Other cashflows from investing activities 0.21M 0.87M - - -
Sale purchase of stock 0.62M - - - -0.23M
Other cashflows from financing activities 218.87M 93.98M 73.08M -2.39M -1.48M
Change to netincome - - - - 1.92M
Capital expenditures 0.16M 0.04M 0.15M 0.61M 0.19M
Change in working capital -1.12M -4.54M 1.40M 0.44M 3.57M
Stock based compensation 34.02M 20.17M 12.91M 3.19M 1.92M
Other non cash items 0.23M -0.12M -4.30M 1.74M 2.06M
Free cash flow -70.46M -73.24M -61.42M -32.69M -19.32M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ELVN
Enliven Therapeutics Inc.		 1.47
2.97%		 50.90 - - - 4.45 -6.28
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Enliven Therapeutics Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

6200 Lookout Road, Boulder, CO, United States, 80301

720 647 8519

https://www.enliventherapeutics.com

67

Name Title Year Born
Mr. Samuel S. Kintz M.B.A. Co-Founder, CEO, Secretary & Director 1986
Mr. Benjamin Hohl CFO & Head of Corporate Development 1989
Dr. Helen Louise Collins M.D. Chief Medical Officer 1963
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder, Chief Scientific Officer & Directors 1965
Mr. Anish Patel Pharm.D. Co-Founder & COO 1980
Dr. Galya D. Blachman Esq., Ph.D. Chief Legal Officer & Head of Business Development 1977
Mr. Samuel S. Kintz M.B.A. Co-Founder & Head of Pipeline 1987
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder & Chief Scientific Officer 1965
Mr. Richard A. Fair CEO, President & Director 1969
Mr. Anish Patel Pharm.D. Co-Founder & COO 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…